Investigational New Drugs

, Volume 21, Issue 1, pp 99–101

Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

  • Robert J. Motzer
  • Robert Amato
  • Mary Todd
  • Wen-J Poo Hwu
  • Roger Cohen
  • Jose Baselga
  • Hyman Muss
  • Michael Cooper
  • Richard Yu
  • Michelle S. Ginsberg
  • Michael Needle
Article

Abstract

Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m2 followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.

renal cell carcinoma Cetuximab C225 monoclonal antibody 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 163: 408–417, 2000Google Scholar
  2. 2.
    Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703–2707, 1997Google Scholar
  3. 3.
    Lager DJ, Slagel DD, Palechek PL: The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 7: 544–548, 1994Google Scholar
  4. 4.
    Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin, DJ: Mouse human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4: 2957–2966, 1998Google Scholar
  5. 5.
    Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289–296, 2002Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Robert J. Motzer
    • 1
  • Robert Amato
    • 2
  • Mary Todd
    • 4
  • Wen-J Poo Hwu
    • 5
  • Roger Cohen
    • 7
  • Jose Baselga
    • 9
  • Hyman Muss
    • 10
  • Michael Cooper
    • 11
  • Richard Yu
    • 1
  • Michelle S. Ginsberg
    • 1
  • Michael Needle
    • 13
  1. 1.Memorial Sloan-Kettering Cancer CenterDepartment of Medicine and Department of RadiologyNew YorkUSA
  2. 2.MD Anderson Cancer InstituteHoustonUSA
  3. 3.Baylor College of MedicineHoustonUSA
  4. 4.Cancer Institute of New JerseyNew BrunswickUSA
  5. 5.Yale University School of MedicineNew HavenUSA
  6. 6.Memorial Sloan-Kettering Cancer CenterUSA
  7. 7.University of Virginia Health SciencesCharlottesvilleUSA
  8. 8.Fox Chase Cancer CenterPhiladelphiaUSA
  9. 9.Vall d'Hebron University HospitalBarcelonaUSA
  10. 10.University of Vermont College of MedicineBurlingtonUSA
  11. 11.University of AlabamaBirminghamUSA
  12. 12.Bristol Myers SquibbWallingfordUSA
  13. 13.ImClone Systems IncorporatedSomervilleUSA

Personalised recommendations